THE 60-SECOND GUIDE
DSIP
Small controlled human study · weak findings.
Guide prepared November 13, 2026 · profile review dates retained
What is it?
Delta sleep-inducing peptide, or DSIP, is an experimental peptide named after early sleep-related animal observations. Its name sounds like a proven effect, but the human insomnia evidence is small and has not established a dependable treatment benefit. [1]
Potential benefits
Historically studied for sleep and stress-related effects. Remains an unusual chapter in peptide research history. [1]
Evidence & its limits
The 1992 trial reported weak changes in some objective sleep measures, with possible influence from changes in the placebo group. Subjective sleep quality did not improve, and the authors did not regard the short-term benefit as clinically substantial. [1]
Risks & unknowns
Physiological significance is uncertain. Human evidence is inconsistent and no approved use exists. [1]
Status & scope
Human evidence is inconsistent and no approved use exists. [1]
The question to ask
Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.
CHECK THE RECORD
Sources & review
- Full evidence record, references and review dates
- Double-blind study in chronic insomnia, 1992
- Original DSIP characterization, 1977
Guide prepared November 13, 2026 · profile review dates retained. Condensed from the linked site evidence record. This format update is not a new clinical review of every source. Consult the full profile for its evidence-review dates and targeted updates.
Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.